Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.
Francisco José de AbajoAntonio Rodríguez-MiguelSara Rodríguez-MartínVictoria LermaAlberto García-Lledónull nullPublished in: BMC medicine (2021)
The discontinuation of ACEIs/ARBs at admission did not improve the in-hospital survival. On the contrary, the continuation with ARBs was associated with a trend to a reduced mortality as compared to their discontinuation and to a significantly lower mortality risk as compared to the continuation with ACEIs, particularly in high-risk patients.
Keyphrases
- end stage renal disease
- cardiovascular events
- healthcare
- newly diagnosed
- angiotensin converting enzyme
- chronic kidney disease
- sars cov
- emergency department
- risk factors
- peritoneal dialysis
- angiotensin ii
- adverse drug
- type diabetes
- cardiovascular disease
- coronary artery disease
- patient reported outcomes
- electronic health record
- free survival